News articles about AxoGen (NASDAQ:AXGN) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AxoGen earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.3922366399947 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- AxoGen, Inc. to Report Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call on February 28, 2018 (feeds.benzinga.com)
- Financial Review: AxoGen (AXGN) & Zynex (ZYXI) (americanbankingnews.com)
- AxoGen, Inc. (AXGN) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- $16.09 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter (americanbankingnews.com)
AXGN has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of AxoGen in a report on Friday, January 5th. Jefferies Group initiated coverage on AxoGen in a report on Thursday, November 30th. They issued a “buy” rating and a $35.00 price target for the company. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Lake Street Capital raised their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Finally, Leerink Swann raised their price target on AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $29.33.
In related news, Director Jamie Mark Grooms sold 38,405 shares of AxoGen stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Guido J. Neels sold 1,150,000 shares of AxoGen stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The disclosure for this sale can be found here. Insiders have sold 1,293,990 shares of company stock valued at $26,494,898 in the last ninety days. Corporate insiders own 9.33% of the company’s stock.
WARNING: “AxoGen (AXGN) Receives Media Sentiment Rating of 0.14” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/02/15/axogen-axgn-receives-media-sentiment-rating-of-0-14.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.